<DOC>
	<DOCNO>NCT01816594</DOCNO>
	<brief_summary>This randomize , parallel cohort , two stage , double-blind , placebo-controlled study evaluate oral PI3K inhibitor BKM120 combination trastuzumab paclitaxel HER2-positive primary breast cancer prior definitive surgery ( neo-adjuvant setting ) .</brief_summary>
	<brief_title>NeoPHOEBE : Neoadjuvant Trastuzumab + BKM120 Combination With Weekly Paclitaxel HER2-positive Primary Breast Cancer</brief_title>
	<detailed_description>NeoPHOEBE evaluate efficacy ( defined pCR ) BKM120 ( oral PI3K inhibitor ) combination trastuzumab paclitaxel randomize , placebo-controlled , neo-adjuvant study woman diagnose primary breast cancer &gt; 1.5 cm ( US MRI ) centrally confirm HER2 overexpression amplification , previously undergone treatment invasive breast cancer . Prior initiation paclitaxel , 6-week `` biologic window '' trastuzumab plus BKM120 placebo . The study conduct separately two cohort ( PIK3CA mutate PI3K3CA wild-type ) use two-stage approach . Within cohort patient randomize one follow treatment arm : Arm 1 : BKM120 placebo plus trastuzumab 6 week follow BKM120 placebo plus trastuzumab plus weekly paclitaxel additional 12 week . Arm 2 : BKM120 plus trastuzumab 6 week follow BKM120 trastuzumab plus weekly paclitaxel additional 12 week . After completion study treatment , patient undergo definitive surgery .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Patient female â‰¥ 18 year age Patient ECOG performance status 01 Patient unilateral ( multifocal multicentric disease allow ) , histologically confirm , newly diagnose early breast cancer &gt; 2cm clinical examination and/or &gt; 1.5 cm confirm ultrasound MRI Patient tumor tissue available central review ER , HER2 PI3K status centrally confirm HER2positive disease know PI3KCA mutation status Patient adequate bone marrow , renal liver function Patient able swallow retain oral medication Patient receive prior systemic treatment currently diagnose disease Patient know contraindication , hypersensitivity intolerance trastuzumab , paclitaxel product contain cremophor Patient bilateral breast cancer metastatic disease inflammatory breast cancer LVEF 50 % determine MUGA scan ECHO Patient active cardiac disease history cardiac abnormality define protocol Patient impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption BKM120 Patient currently receive warfarin coumarin derive anticoagulant Patient currently receive chronic treatment corticosteroid another immunosuppressive agent ( standard premedication paclitaxel local application allow ) Patient currently receive treatment drug know strong inhibitor inducer CYP3A Patient certain score anxiety depression mood questionnaire Pregnant nursing ( lactate ) woman patient willing apply apply highly effective contraception define protocol Other protocol define criterion may apply</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HER2 , breast cancer , neoadjuvant , PI3K inhibitor , first line chemotherapy , trastuzumab , GBG , SOLTI , BIG</keyword>
</DOC>